川崎病冠状动脉病变的高危因素和随访管理(3)
 |
| 第1页 |
参见附件。
[11] Chaiyarak K，Durongpisitkul K， et al. Clinical manifestations of Kawasaki disease： What are the significant parameters. Asian pacific journal of allergy and immunology，2009.27(2-3)：131-136.
[12] De Rosa G Pardeo M， Rigante D. Current recommendations for the pharmacologic therapy
in Kawasaki syndrome and management of its cardiovascular complications[J]. Eur RevMed
Pharmacol Sci. 2007， 11(5)：301-8.
[13] 谢利剑，俞岑妍，马晓静，等.Cardiac/coronary artery lesion in Kawasaki disease treated with different kind of intravenous immunoglobulin therapy in Shanghai from 1998-2008.临床儿科杂志，2009，27(10)：901-905.
[14] 黄国英.冠状动脉并发症的诊断[M].杜忠东.川崎病.北京：科学技术文献出版社，2009：131-135.
[15] Japanese Circulation Society Joint Research Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease[J].Pediatr Int，2005，47(6)：711-714.
[16] Satou GM， Giamelli J， Gewitz MH， et al. Kawasaki disease： diagnosis， management， and long-term implications[J].Cardiol Rev，2007，15(4)：163-169.
[17] Newburger JW， Takahashi M， Gerber MA，et al.Diagnosis，treatment， and long-term management of Kawasaki disease： a statement for health professionals from the committee on rheumatic fever， endocarditis， and Kawasaki disease， council on cardiovascular disease in the young， American Heart Association[J].Pediatrics，2004，114(6)：1708-1733.
[18] Tsuda E， Kamiya T， Ono Y， et al. Incidence of stenotic lesions predicted by acute phase changes in coronary arterial diamete during Kawasaki disease[J]. Pediat Cardiol，2005，26(1)：73-79
您现在查看是摘要介绍页，详见PDF附件。